VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Males and females age ≥18 years in second relapse  │ Males and females age ≥18 years in second relapse  │     100 │
│ or refractory                                      │ or refractory                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Males and females age ≥60 years in first relapse   │ Males and females age ≥60 years in first relapse   │     100 │
│ or refractory                                      │ or refractory                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have baseline bone marrow sample taken        │ Must have baseline bone marrow sample taken        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Morphologically documented primary AML or AML      │ Morphologically documented primary AML or AML      │     100 │
│ secondary to myelodysplastic syndrome (MDS with    │ secondary to myelodysplastic syndrome (MDS with    │         │
│ ≥20% bone marrow or peripheral blasts), as defined │ ≥20% bone marrow or peripheral blasts), as defined │         │
│ by the World Health Organization (WHO) criteria,   │ by the World Health Organization (WHO) criteria,   │         │
│ confirmed by pathology review at treating          │ confirmed by pathology review at treating          │         │
│ institution                                        │ institution                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Able to swallow the liquid study drug              │ Able to swallow the liquid study drug              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In the absence of rapidly progressing disease, the │ In the absence of rapidly progressing disease, the │     100 │
│ interval from prior treatment to time of AC220     │ interval from prior treatment to time of AC220     │         │
│ administration will be at least 2 weeks for        │ administration will be at least 2 weeks for        │         │
│ cytotoxic agents or at least 5 half-lives for      │ cytotoxic agents or at least 5 half-lives for      │         │
│ noncytotoxic agents. The use of chemotherapeutic   │ noncytotoxic agents. The use of chemotherapeutic   │         │
│ or antileukemic agents other than hydroxyurea is   │ or antileukemic agents other than hydroxyurea is   │         │
│ not permitted during the study with the possible   │ not permitted during the study with the possible   │         │
│ exception of intrathecal (IT) therapy at the       │ exception of intrathecal (IT) therapy at the       │         │
│ discretion of the Investigator and with the        │ discretion of the Investigator and with the        │         │
│ agreement of the Sponsor                           │ agreement of the Sponsor                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persistent chronic clinically significant non-     │ Persistent chronic clinically significant non-     │     100 │
│ hematological toxicities from prior treatment must │ hematological toxicities from prior treatment must │         │
│ be ≤Grade 1                                        │ be ≤Grade 1                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior therapy with FLT3 inhibitors is permitted,   │ Prior therapy with FLT3 inhibitors is permitted,   │     100 │
│ except previous treatment with AC220               │ except previous treatment with AC220               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum potassium, magnesium, and calcium levels     │ Serum potassium, magnesium, and calcium levels     │     100 │
│ should be at least within institutional normal     │ should be at least within institutional normal     │         │
│ limits                                             │ limits                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Total serum bilirubin ≤1.5 × ULN                   │ Total serum bilirubin ≤1.5 × ULN                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum aspartate transaminase (AST) and/or alanine  │ Serum aspartate transaminase (AST) and/or alanine  │     100 │
│ transaminase (ALT) ≤2.5 × ULN                      │ transaminase (ALT) ≤2.5 × ULN                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females of childbearing potential must have a      │ Females of childbearing potential must have a      │     100 │
│ negative pregnancy test (urine β-hCG)              │ negative pregnancy test (urine β-hCG)              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females of childbearing potential and sexually     │ Females of childbearing potential and sexually     │     100 │
│ mature males must agree to use a medically         │ mature males must agree to use a medically         │         │
│ accepted method of contraception throughout the    │ accepted method of contraception throughout the    │         │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Written informed consent must be provided          │ Written informed consent must be provided          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients over the age of 85 years except at the    │ Patients over the age of 85 years except at the    │     100 │
│ discretion of the Investigator and with agreement  │ discretion of the Investigator and with agreement  │         │
│ of the Sponsor                                     │ of the Sponsor                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of acute promyelocytic leukemia          │ Diagnosis of acute promyelocytic leukemia          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of chronic myelogenous leukemia (CML) in │ Diagnosis of chronic myelogenous leukemia (CML) in │     100 │
│ blast crisis                                       │ blast crisis                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ AML in relapse or refractory after 3 or more       │ AML in relapse or refractory after 3 or more       │     100 │
│ previous lines of chemotherapy (and/or HSCT)       │ previous lines of chemotherapy (and/or HSCT)       │         │
│ treatment                                          │ treatment                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ AML or antecedent MDS secondary to prior           │ AML or antecedent MDS secondary to prior           │     100 │
│ chemotherapy                                       │ chemotherapy                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persistent clinically significant non-             │ Persistent clinically significant non-             │     100 │
│ hematological toxicity that is Grade \>1 by NCI    │ hematological toxicity that is Grade >1 by NCI     │         │
│ CTCAE v4 from prior chemotherapy                   │ CTCAE v4 from prior chemotherapy                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have had HSCT and are within 100 days │ Patients who have had HSCT and are within 100 days │     100 │
│ of transplant and/or are still taking              │ of transplant and/or are still taking              │         │
│ immunosuppressive drugs and/or have clinically     │ immunosuppressive drugs and/or have clinically     │         │
│ significant graft-versus-host disease requiring    │ significant graft-versus-host disease requiring    │         │
│ treatment and/or have \>Grade 1 persistent non     │ treatment and/or have >Grade 1 persistent non      │         │
│ hematological toxicity related to the transplant   │ hematological toxicity related to the transplant   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically active central nervous system (CNS)     │ Clinically active central nervous system (CNS)     │     100 │
│ leukemia. Patients with CNS leukemia, which is     │ leukemia. Patients with CNS leukemia, which is     │         │
│ controlled, but who are still receiving IT therapy │ controlled, but who are still receiving IT therapy │         │
│ at study entry may be considered eligible and      │ at study entry may be considered eligible and      │         │
│ continue receive IT therapy at the discretion of   │ continue receive IT therapy at the discretion of   │         │
│ the Investigator and with agreement of the Sponsor │ the Investigator and with agreement of the Sponsor │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have previously received AC220        │ Patients who have previously received AC220        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Disseminated intravascular coagulation (DIC)       │ Disseminated intravascular coagulation (DIC)       │     100 │
│ (diagnosis by laboratory or clinical assessment)   │ (diagnosis by laboratory or clinical assessment)   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major surgery within 4 weeks prior to enrollment   │ Major surgery within 4 weeks prior to enrollment   │     100 │
│ in the study                                       │ in the study                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Radiation therapy within 4 weeks prior to, or      │ Radiation therapy within 4 weeks prior to, or      │     100 │
│ concurrent with study                              │ concurrent with study                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled or significant cardiovascular disease │ Uncontrolled or significant cardiovascular disease │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are pregnant, lactating, or unwilling to │ Women who are pregnant, lactating, or unwilling to │     100 │
│ use contraception if of childbearing potential     │ use contraception if of childbearing potential     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Men who are unwilling to use contraception if      │ Men who are unwilling to use contraception if      │     100 │
│ their partners are of childbearing potential       │ their partners are of childbearing potential       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active, uncontrolled infection                     │ Active, uncontrolled infection                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Human immunodeficiency virus positivity            │ Human immunodeficiency virus positivity            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active hepatitis B or C or other active liver      │ Active hepatitis B or C or other active liver      │     100 │
│ disease                                            │ disease                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of cancer, except Stage 1 cervix or        │ History of cancer, except Stage 1 cervix or        │     100 │
│ nonmelanotic skin cancer, with the possible        │ nonmelanotic skin cancer, with the possible        │         │
│ exception of patients in complete remission        │ exception of patients in complete remission        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum creatinine ≤1.5 × upper limit of normal      │ Serum creatinine ≤1.5 × ULN and glomerular         │      86 │
│ (ULN) and glomerular filtration rate (GFR) \> 30   │ filtration rate (GFR) > 30 mL/min                  │         │
│ mL/min                                             │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤═════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                   │   Score │
╞════════════════════════════════════════════════════╪═════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                  │ Must have baseline bone marrow sample taken     │      50 │
├────────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 85 Years                  │ Must have baseline bone marrow sample taken     │      50 │
├────────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Eastern Cooperative Oncology Group performance     │ ECOG performance status of 0 to 2               │      69 │
│ status of 0 to 2                                   │                                                 │         │
├────────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Use of concomitant drugs that prolong the time     │ Use of concomitant drugs that prolong QT/QTc    │      84 │
│ between the start of the Q wave and the end of the │ interval and/or are CYP3A4 inhibitors are       │         │
│ T wave (QT)/corrected interval between the Q wave  │ prohibited with the exception of antibiotics,   │         │
│ and T wave (QTc) interval and/or are CYP3A4        │ antifungals, and other antimicrobials that are  │         │
│ inhibitors are prohibited with the exception of    │ used as standard of care to prevent or treat    │         │
│ antibiotics, antifungals, and other antimicrobials │ infections and other such drugs that are        │         │
│ that are used as standard of care to prevent or    │ considered absolutely essential for the care of │         │
│ treat infections and other such drugs that are     │ the patient                                     │         │
│ considered absolutely essential for the care of    │                                                 │         │
│ the patient                                        │                                                 │         │
╘════════════════════════════════════════════════════╧═════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤═════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                   │   Score │
╞════════════════════════════════════════════════════╪═════════════════════════════════════════════════╪═════════╡
│ Eastern Cooperative Oncology Group performance     │ ECOG performance status of 0 to 2               │      69 │
│ status of 0 to 2                                   │                                                 │         │
├────────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Use of concomitant drugs that prolong the time     │ Use of concomitant drugs that prolong QT/QTc    │      84 │
│ between the start of the Q wave and the end of the │ interval and/or are CYP3A4 inhibitors are       │         │
│ T wave (QT)/corrected interval between the Q wave  │ prohibited with the exception of antibiotics,   │         │
│ and T wave (QTc) interval and/or are CYP3A4        │ antifungals, and other antimicrobials that are  │         │
│ inhibitors are prohibited with the exception of    │ used as standard of care to prevent or treat    │         │
│ antibiotics, antifungals, and other antimicrobials │ infections and other such drugs that are        │         │
│ that are used as standard of care to prevent or    │ considered absolutely essential for the care of │         │
│ treat infections and other such drugs that are     │ the patient                                     │         │
│ considered absolutely essential for the care of    │                                                 │         │
│ the patient                                        │                                                 │         │
╘════════════════════════════════════════════════════╧═════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 94.8
OverAll Ratio: 95.9
